Jeff Yass’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-296,900
| Closed | -$9.94M | – | 14432 |
|
|
2026
Q1 | $9.94M | Buy |
296,900
+42,000
| +16% | +$1.65M | ﹤0.01% | 3129 |
|
|
2025
Q4 | $11.8M | Sell |
254,900
-146,800
| -37% | -$8.05M | ﹤0.01% | 2847 |
|
|
2025
Q3 | $27.2M | Buy |
401,700
+6,800
| +2% | +$504K | ﹤0.01% | 1887 |
|
|
2025
Q2 | $33.1M | Sell |
394,900
-526,400
| -57% | -$39.4M | ﹤0.01% | 1511 |
|
|
2025
Q1 | $65.8M | Sell |
921,300
-207,600
| -18% | -$10.1M | 0.01% | 871 |
|
|
2024
Q4 | $50.7M | Buy |
1,128,900
+769,000
| +214% | +$39.8M | 0.01% | 1108 |
|
|
2024
Q3 | $18.2M | Buy |
359,900
+334,400
| +1,311% | +$16M | ﹤0.01% | 1929 |
|
|
2024
Q2 | $1.04M | Sell |
25,500
-231,300
| -90% | -$9.8M | ﹤0.01% | 6492 |
|
|
2024
Q1 | $11M | Buy |
256,800
+246,400
| +2,369% | +$11.1M | ﹤0.01% | 2478 |
|
|
2023
Q4 | $419K | Buy |
+10,400
| New | +$296K | ﹤0.01% | 9091 |
|
|
2023
Q1 | – | Sell |
-11,100
| Closed | -$22K | – | 13424 |
|
|
2022
Q4 | $22K | Hold |
11,100
| – | – | ﹤0.01% | 11735 |
|
|
2022
Q3 | $19K | Buy |
11,100
+10,360
| +1,400% | +$25.2K | ﹤0.01% | 12622 |
|
|
2022
Q2 | $2K | Sell |
740
-67
| -8% | -$185 | ﹤0.01% | 12690 |
|
|
2022
Q1 | $3K | Sell |
807
-1,340
| -62% | -$6.94K | ﹤0.01% | 12852 |
|
|
2021
Q4 | $13K | Sell |
2,147
-5,120
| -70% | -$53.7K | ﹤0.01% | 12898 |
|
|
2021
Q3 | $101K | Sell |
7,267
-300
| -4% | -$4.18K | ﹤0.01% | 12067 |
|
|
2021
Q2 | $129K | Buy |
7,567
+5,754
| +317% | +$97.2K | ﹤0.01% | 11942 |
|
|
2021
Q1 | $34K | Buy |
1,813
+846
| +87% | +$27.3K | ﹤0.01% | 12094 |
|
|
2020
Q4 | $28K | Sell |
967
-5,066
| -84% | -$146K | ﹤0.01% | 10855 |
|
|
2020
Q3 | $227K | Sell |
6,033
-5,114
| -46% | -$149K | ﹤0.01% | 9257 |
|
|
2020
Q2 | $371K | Buy |
+11,147
| New | +$483K | ﹤0.01% | 7964 |
|
Jeff Yass's SLNO Position: Q2 2026 in Review
Jeff Yass sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 549,877 shares — an estimated $18.4M sold.
Jeff Yass first reported a position in SLNO in Q1 2017 and held it in 23 quarters. The position peaked at $34.6M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Jeff Yass reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 549,877 Soleno Therapeutics shares in Q2 2026, an estimated $18.4M.
- Jeff Yass first reported a position in Soleno Therapeutics in Q1 2017 and held it in 23 quarters.
- Jeff Yass's Soleno Therapeutics position peaked at $34.6M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.